Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Homologous Recombination Deficiency (HRD) scores evaluated in 15 high grade ovarian cancer samples

From: Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes

ID tAI LOH LST CS
1 11 4 15 30
2 13 5 10 28
3 15 3 9 27
4 36 25 22 83
5 48 28 28 104
6a 39 15 30 84
7a 33 22 32 87
8a 12 5 13 30
9 35 14 28 77
10 40 19 26 85
11 15 0 28 43
12 15 6 9 30
13 31 9 24 64
14 8 4 5 17
15a 33 16 29 78
Median (P25–75) 31.0 (13–36) 9.0 (4–19) 24.0 (10–28) 64 (30–84)
  1. tAI elomeric allellic imbalance score, LOH loss of heterozygosity score, LST large scale transition score, CS composite score, P25–75 interquartile range. The cut-off values were the median 30 for tAI, > 10 for LOH, > 42 for CS and > 15 for near-diploid tumors or > 20 for near-tetraploid tumors for LST scores
  2. aBRCA1 mutated